Artificial Heart Market Research: 2035

The global artificial heart market was valued at $3.1 billion in 2024, and is projected to reach $9.0 billion by 2035, growing at a CAGR of 9.5% from 2024 to 2035. Artificial hearts are mechanical devices that are implanted into patients to partially or completely replace a failing heart. When transplantation is not immediately available, these devices can save the lives of people with end-stage heart failure. For patients not eligible for heart transplants, these systems act as a bridge-to-transplantation (BTT) or, in certain situations, as destination therapy (DT).

An aging population, an increase in cardiovascular diseases (CVDs) worldwide, and a continuing discrepancy between the demand and supply for organ transplants are all contributing factors to the growing demand for artificial hearts. The WHO reports that heart failure is still one of the world’s leading causes of death, and the scarcity of donor hearts emphasizes the need for workable substitutes. Ventricular assist devices (VADs) and total artificial hearts (TAHs) in particular are becoming recognized as game-changing medical innovations that can increase life expectancy and enhance the quality of life for patients in critical condition.

The performance and dependability of artificial heart devices have greatly increased in recent years due to quick developments in biocompatible materials, tiny electronics, and wireless power systems. Adoption is also being accelerated in healthcare systems around the world by expanding government support for cardiac research, advantageous reimbursement schemes in developed markets, and the introduction of ground-breaking products by major medical device manufacturers.

Coverage of the report

Key Benefits for Stakeholders     

This comprehensive report provides stakeholders with in-depth qualitative and quantitative analyses, focusing on the artificial heart market from 2021 to 2035.

Key benefits include:

• Insightful Artificial Heart Market Forecast: The report offers detailed projections, covering various segments, current trends, and market dynamics.
• Competitive Analysis with Porter’s Five Forces: A thorough examination of the bargaining power of buyers and suppliers, the threat of new entrants, competitive rivalry, and substitute products.
• Comprehensive Market Overview: Gain access to crucial information about key market drivers, restraints, and opportunities.
• Regional and Country-Level Mapping: The report maps out major regions and countries based on their revenue contribution to the global artificial heart market.
• Market Player Positioning: The competitive landscape analysis provides a clear understanding of the current market positioning of key players.

Key Market Drivers and Growth Factors in the Artificial Heart Market

Several convergent trends are driving the artificial heart market. Crucially, there is an urgent need for mechanical cardiac support due to the increased prevalence of cardiovascular diseases (CVDs), which include heart failure, coronary artery disease, and hypertension. Nearly 18 million deaths worldwide are attributed to CVDs each year, making up nearly 32% of all deaths, according to the WHO. Given the continued scarcity of donor hearts (fewer than 8,500 transplants worldwide in 2023), the market for mechanical and bioprosthetic hearts has emerged as a life-saving substitute.

Demand is also being fueled by the world’s aging population. According to UN projections, the number of people 65 and older will rise to almost 2 billion by 2050, particularly in developed countries, which will result in a higher prevalence of heart failure. Strong pulse is also observed in Asia-Pacific, where nations like China, India, and Japan are placing more emphasis on cardiac care, growing their healthcare infrastructure, and increasing their disposable incomes.

Challenges and Restraints in the Artificial Heart Market

There are still a number of restrictions in place despite its encouraging growth. First off, a significant obstacle is the high expense of artificial heart procedures and devices, which can range from $54,000 to over 100,000, particularly in developing nations with little insurance coverage. Patients and hospitals frequently have to pay high costs for surgery and follow-up care.
Further, adoption in long-term applications is still hampered by safety issues and complication risks like infection, bleeding, and device thrombosis. Additionally, inconsistent reimbursement practices slow acceptance in many regions. Another obstacle is regulatory delays. Despite advancements in clinical trials, many next-generation devices still lack FDA or CE certification, which could delay the systems’ widespread adoption.

Technological Advancements in the Artificial Heart Market

In many ways, technological developments are transforming the artificial heart market. Total artificial hearts (TAHs) powered by maglev are among the most important innovations. With a noteworthy instance in Australia where a patient who had been supported by BiVACOR’s titanium maglev TAH for more than 100 days was able to successfully receive a donor heart, the device has shown promise for long-term bridge-to-transplant use. As evidence of the growing trust in magnetic levitation technology, the U.S.-based company is now growing its FDA-approved clinical trials.

At the same time, TAHs are becoming more patient-friendly due to their miniaturization and fully implantable systems. Devices such as the miniaturized 50 cc TAH from SynCardia are more appropriate for patients with limited anatomical space or who are smaller in stature and consume less power. Additionally, BiVACOR is making strides toward the creation of fully implantable artificial hearts, which would do away with the requirement for external drivelines, a long-standing drawback of existing systems.

The durability and safety of devices are being enhanced by developments in biocompatible materials. For example, the CE-marked Aeson TAH implanted in France in late 2023 by Carmat GmbH has biocompatible cushioning that reduces clot formation and immunological rejection, thus increasing implant longevity.

At the same time, smart technologies are being integrated into next-generation LVADs (left ventricular assist devices). SmartAssist systems, which enable adaptive control and real-time monitoring, are now included with Abiomed’s Impella and Abbot’s HeartMate 3 pumps. Prominent surgical achievements, like the quick multi-VAD implantations at Tampa General Hospital, demonstrate the increasing clinical confidence in these cutting-edge systems.

Furthermore, device regulation is changing as a result of the advent of AI-driven, sensorless control technology. Without the use of physical sensors, deep learning algorithms can now control flow rates, simplifying systems and improving physiological accuracy and dependability.

Regenerative soft robotics is a promising field where EU-funded projects, such as the HybridHeart project, are developing artificial hearts that use biocompatible, inflatable chambers to replicate natural muscular contractions. A step toward more flexible and natural cardiac implants is represented by these soft-robotic systems.

Notably, Israel-based Magenta Medical raised $105 million in July 2024 to expedite trials of its miniature Impella-style heart pump, intended for patients with cardiogenic shock and high-risk PCI. A new global standard for artificial heart support was set in February 2025 when a patient at St. Vincent’s Hospital in Australia became the first to leave the hospital after surviving for more than 100 days on a BiVACOR TAH.

Artificial Heart Market Segmentation

By product type, the artificial heart market is divided into total artificial hearts (TAHs) and ventricular assist devices (VADs). The ventricular assist devices (VADs) market segment had the biggest market share in 2024. Because left ventricular assist devices (LVADs) are frequently used as destination or bridge-to-transplant therapies, particularly in patients with severe left-sided heart failure, this dominance is explained. Abiomed’s Impella and Abbott’s HeartMate 3 are two examples of LVADs that have experienced significant clinical adoption because of their increased survival rates, dependability, and technological advancements.

Nonetheless, the total artificial heart (TAH) market is anticipated to expand at the quickest rate over the course of the forecast period due to continuous advancements in fully implantable devices, such as the Aeson from Carmat and the maglev-powered heart from BiVACOR, which are being introduced to treat complete biventricular failure.

By type, the market is segmented into implantable artificial hearts and external artificial hearts. Due to their capacity to provide sustained support and enhanced patient mobility, implantable artificial hearts dominated the market in 2024. Patients with implanted hearts enjoy longer lifespans and improved quality of life, particularly in nations with generous reimbursement policies. Even though the external artificial heart market is still relatively small, it is anticipated to expand quickly, especially in developing nations where non-invasive, short-term solutions are preferred over permanent surgery or transplantation.

The artificial heart market is segmented by therapy into Bridge to Transplant (BTT), Destination Therapy (DT), Bridge to Decision (BTD), and Others. Due to its crucial role in keeping patients waiting for heart transplants afloat in the face of donor shortages, BTT has the largest share. This is where devices like SynCardia’s TAHs and BiVACORs are frequently utilized. With improvements in fully implantable and AI-integrated systems, as well as an increase in heart failure cases and patients who are not eligible for transplants, DT is the market segment with the fastest rate of growth.

In emergency situations, BTD is a temporary fix for assessing long-term treatment alternatives. The Others segment contains temporary and experimental support devices that demonstrate promise through continued innovation and research. The advancement of cardiac care is influenced differently by each type of therapy.

By end user, the artificial heart market is segmented into hospitals, specialty cardiac centers, and others. The ability of hospitals to provide both post-operative care and sophisticated cardiac surgical procedures under one roof allowed them to dominate the market in 2024. Additionally, hospitals with specialized infrastructure are used for the majority of clinical trials, device implantations, and transplants. Because of its expertise in managing heart failure, patient-centered care, and increasing investment in high-tech surgical units, the specialty cardiac centers segment is anticipated to grow at the fastest rate, especially in developed countries.

Regional Analysis of the Global Artificial Heart Market

The global artificial heart market is geographically segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa (MEA). Each region exhibits unique dynamics based on healthcare infrastructure, regulatory support, technology adoption, and the burden of cardiovascular disease.

In 2024, North America, comprising the U.S. and Canada, accounted for the largest share of the global artificial heart market. The region’s established healthcare system, the prevalence of advanced heart failure, and the presence of major players like Abbott, Abiomed, and SynCardia are all factors contributing to its dominance. Due to favorable FDA approvals, clinical trials, and extensive Medicare reimbursement policies, the use of LVADs and TAHs has increased, especially in the United States. In addition, Canada is seeing a rise in cardiac research and innovation participation, which supports consistent regional growth.

The UK, Germany, France, and Italy are important markets in Europe, which also contribute significantly to the artificial heart market revenue. The European market is driven by the existence of CE-approved products, such as Carmat’s Aeson TAH, and policies that are supportive of the treatment of heart failure. While France and the UK continue to invest in hospital-based cardiac innovation hubs, Germany is the world leader in the production and use of sophisticated mechanical circulatory support devices. Government-led efforts to combat cardiovascular mortality and aging populations are also driving growth in this region.

During the forecast period, the Asia-Pacific region, led by nations like China, Japan, India, and South Korea, is expected to grow at the fastest rate. Regional momentum is being driven by rising healthcare costs, rising CVD prevalence, increased access to sophisticated surgical procedures, and growing knowledge of artificial heart technologies. Japan is a major user of ventricular assist devices because of its advanced healthcare system and aging population. In the meantime, domestic R&D collaborations and the volume of cardiac surgeries performed in China and India are increasing, creating new prospects for both domestic and international manufacturers.

With increased investment in tertiary care facilities and a growing need for sophisticated cardiac procedures, Latin American nations like Brazil, Mexico, and Argentina are gradually catching up. However, due to disparities in insurance coverage and cost barriers, the adoption of artificial hearts in this region is still comparatively limited. Accessibility is expected to improve in the upcoming years, thanks to regional clinical studies and partnerships with multinational corporations.

Incremental growth is also occurring in the Middle East & Africa (MEA) region, which includes South Africa, Kenya, the United Arab Emirates, and Saudi Arabia. Regional development is being aided by the rise of specialty hospitals in Gulf countries, high rates of heart disease, and a growing emphasis on modernizing healthcare. While African countries are mainly concerned with increasing access to primary and secondary cardiac care, Saudi Arabia and the United Arab Emirates are making significant investments in cutting-edge cardiac facilities and digital health integration.

Competition Analysis of the Global Artificial Heart Market

Leading companies profiled in the report are Abiomed Inc., Abbott Laboratories, Berlin Heart GmbH, BiVACOR Inc., Bivona Medical Technologies, Calon Cardio-Technology Ltd., Carmat SA, CH Biomedical Inc., Cryolife Inc., Jarvik Heart Inc., Medtronic plc, SynCardia Systems LLC, Thoratec Corporation (acquired by Abbott), and Zoll Medical Corporation. With an emphasis on enhancing biocompatibility, decreasing device size, and prolonging operational lifespans, these businesses are spearheading developments in ventricular assist devices (VADs), total artificial hearts (TAHs), and next-generation implantable circulatory support systems. To improve patient outcomes and broaden access to international markets, many of them are also making investments in fully implantable wireless platforms, remote monitoring, and AI integration.

Key Developments/ Strategies in the Artificial Heart Market

• In July 2024, BiVACOR used an FDA-approved Early Feasibility Study (EFS) to perform the first human implantation of its titanium Total Artificial Heart (TAH) at Baylor St. Luke’s Medical Center in Houston. After eight days, the patient was able to bridge to the transplant successfully.
• As part of the FDA EFS program, BiVACOR reported that its TAH had been successfully implanted in five patients in December 2024. This led to FDA approval to expand the trial to include fifteen more participants.
• Australia’s first BiVACOR TAH implant was performed at St. Vincent’s Hospital in Sydney in November 2024. This was followed by the longest known TAH use prior to transplantation, a record-breaking 105-day support period.
• When BiVACOR’s TAH was granted FDA Breakthrough Device Designation in May 2025, it marked a significant regulatory milestone and was recognized as a priority device that could greatly improve outcomes for patients suffering from irreversible heart failure.
• In June 2024, Carmat named Pierre Bastid, a major shareholder, as chairman of the board, demonstrating strategic leadership support in the face of capital management difficulties.
• A significant financial turning point was reached in June 2025 when Carmat disclosed a liquidity crisis and acknowledged that the company was at risk of payment cessation if it did not secure an additional ~$3.5 million by month’s end.